Table 3 AA139 assessed for antimicrobial activity against two clinical isolate panels.

From: An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria

US isolates 2010–2012

Species

Description

n

AA139a

GEN

CFZ

MER

CIP

COL

E. coli

Non-MDR

24

2

8

2

0.03

>4

4b

MDR

31

0.5

>32

>32

16

>4

0.5b

K. pneumoniae

Non-MDR

24

4

8

1

0.06

>4

16b

XDR

55

2

>32

>32

>16

>4

0.5b

P. aeruginosa

Non-MDR

41

8

>32

32

16

>4

4

XDR

37

4

>32

>32

>16

>4

2

A. baumannii

Non-MDR

69

2

>32

>32

>16

>4

2

MDR

19

1

>32

>32

>16

>4

1

XDR

31

0.5

>32

>32

>16

>4

32

Worldwide isolates 2011–2013

Bacteria

Resistance

n

AA139a

GEN

CFZ

MER

LEV

POL

E. coli

c

112

0.5

32

32

0.03

16

0.03b

K. pneumoniae

c

114

4

>32

>32

>16

>32

0.06b

P. aeruginosa

c

111

8

>32

>32

>16

>32

0.25

A. baumannii

c

108

2

>32

>32

>16

>32

0.12

  1. Antimicrobial activity of AA139 and comparator antibiotics against Gram-negative bacterial panels is displayed as MIC90 μg mL−1. Top: 331 isolates selected from US isolates 2010–2012 panel; bottom: 445 isolates selected from worldwide isolates 2011–2013 panel. Source data are provided as a source data file.
  2. MIC in bold indicates resistance (CLSI breakpoints).
  3. S susceptible, MDR resistant to 3–4 classes, XDR resistant to >4 classes, CFZ ceftazidime, CIP ciprofloxacin, COL colistin, GEN gentamycin, LEV levofloxacin, MER meropenem, POL polymyxin B.
  4. aNo breakpoints defined.
  5. bNo CLSI breakpoint defined, EUCAST COL breakpoint applied.
  6. cMIC90 calculated for Worldwide isolates per species including non-MDR, MDR, and XDR strains of each species (Supplementary Table 3).
Back to article page